Soluble CD30 and CD26/DPPIV enzyme activity levels predict treatment outcome with interferon-alpha monotherapy and interferon-alpha/ribavirin combination therapy in chronic Hepatitis C virus (HCV) infection

Silvia Lee, G.C. Macquillan, N.M. Keane, G.P. Jeffrey, Patricia Price

    Research output: Chapter in Book/Conference paperOther chapter contribution

    Original languageEnglish
    Title of host publicationThe Twelfth Annual Combined Biological Sciences Meeting, Perth 2001
    EditorsB. Knight
    Place of PublicationPerth, WA
    Publication statusPublished - 2001

    Cite this